Biomarin Pharmaceutical (bmrn 1.25 05/15/27)
13F holders, Q1 2024 (March 31)15holders
$5.68avg. 13F price*
At the end of Q1 2024, 15 institutions reported holding Biomarin Pharmaceutical (bmrn 1.25 05/15/27) in their 13F filings. The largest holders were Loomis Sayles & Co. L P ($182.4M), Thrivent Financial for Lutherans ($11.9M) and Sonora Investment Management Group, LLC ($9.9M).
- Company
- Biomarin Pharmaceutical (bmrn 1.25 05/15/27)
- CUSIP
- 09061GAK7
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $125K |
| Exits | 3 | $3.2M |
Ownership 15 holders
| Loomis Sayles & Co. L P | 0.26% | Add +1.7% | 2,088,044 | $182.4M |
| Thrivent Financial for Lutherans | 0.02% | Reduce -10.6% | 12,025,000 | $11.9M |
| Sonora Investment Management Group, LLC | 0.78% | Reduce -5.0% | 9,930,000 | $9.9M |
| New York State Common Retirement Fund | 0.01% | No change | 4,606,000 | $4.5M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 4,400,000 | $4.4M |
| Rational Advisors, Inc. | 0.23% | No change | 2,493,000 | $2.5M |
| Ofi Invest Asset Management | 0.05% | Add +100000.0% | 1,001,000 | $1.9M |
| Liberty Mutual Group Asset Management Inc. | 0.29% | No change | 1,025,000 | $1.0M |
| Sei Investments Co. | 0.00% | No change | 653,000 | $644K |
| Bank of New York Mellon Corp | 0.00% | No change | 300,000 | $298K |
| Cetera Investment Advisers | 0.00% | New | 117,000 | $115K |
| Capital Investment Advisors, LLC | 0.00% | No change | 11,000 | $11K |
| DAVENPORT & Co LLC | 0.00% | Add +9900.0% | 10,000 | $10K |
| Envestnet Asset Management Inc. | 0.00% | New | 10,000 | $10K |
| Northwestern Mutual Wealth Management Co. | 0.00% | Reduce -36.4% | 7,000 | $7K |
"% of holder's portfolio" is BIOMARIN PHARMACEUTICAL (BMRN 1.25 05/15/27)'s weight in each manager's 13F, not the share of Biomarin Pharmaceutical (bmrn 1.25 05/15/27) the manager owns.